The theme of this webinar focuses on exploring the current state of the Oncology European Real-World Evidence (RWE) landscape and how IQVIA is contributing to advancements in cancer research in this space. It aims to shed light on the growing importance of RWE in oncology and how IQVIA has developed capabilities to help solve the current challenges in the European data landscape. It will also look ahead at the future challenges in the oncology RWE space and how strong networks, partnerships and future IQVIA technologies can help solve them.
Key points covered:
- An overview of the European RWE landscape (including trends, data availability & linkage expected, as well as RWE methodologies for insight generation in the European context- and how these can be used to support payer and regulatory evidence, inc. for external comparators)
- Discuss how IQVIA has looked to overcome RWE challenges for our clients to improve patient outcomes- including case studies and overviews of posters to be presented at ESMO 2023
- Consider the future for precision oncology data (both near and longer term), including the potential to access biosamples at scale in multiple European countries with linked clinical data
- Hear from some of our partners on what they’re doing to support evolving precision oncology research needs in Europe
Speakers:
Joanne Hackett
Vice President and Head of Genomic and Precision Medicine, IQVIA
Rudiger Papsch
Senior Principal, Integrated Real World Evidence and Solutions, Europe, Middle East and Africa, IQVIA
Lawrence Farrell
Associate Principal, Oncology Evidence Network, Europe, Middle East and Africa, IQVIA
Saskia Hagenaars
Senior Consultant in Epidemiology, IQVIA
Kate Witkowska
Senior Partnerships Director, Genomics England